Javascript must be enabled to continue!
S6 ribosomal protein phosphorylation is associated with malignancy of intraductal papillary mucinous neoplasm of the pancreas
View through CrossRef
AbstractBackgroundGlucose metabolism of intraductal papillary mucinous neoplasms (IPMNs) of the pancreas is unclear. S6 ribosomal protein (S6) phosphorylation is involved not only in controlling cell growth but also in glucose metabolism in cancer. The aim of this study was to investigate the role of S6 phosphorylation and the significance of glucose metabolic changes in IPMN.MethodsRecords of 39 patients who underwent preoperative FDG‐PET and curative resection were enrolled in this study. S6 phosphorylation and GLUT1 expression were evaluated immunohistochemically in these patients. The effect of S6 phosphorylation on glucose uptake was examined in cancer cell lines. To examine the change of glucose metabolism in IPMN clinically, the relation between clinical factors including FDG‐PET and malignancy of IPMN was investigated.ResultsS6 phosphorylation and GLUT1 expression were significantly higher in carcinoma than in normal cells or adenoma. Cell lines with high level of S6 phosphorylation showed high glucose uptake, and inhibition of S6 phosphorylation reduced glucose uptake. In clinical examination, FDG‐PET was the independent factor related to the diagnosis of adenoma or carcinoma (odds ratio = 20.0, 95% confidence interval = 1.837‐539.9, P = .012). FDG‐PET detected carcinoma with a sensitivity of 81.8%, specificity of 96.4%, and accuracy of 92.3%.ConclusionS6 phosphorylation was associated with glucose uptake and malignancy of IPMN. Moreover, glucose uptake increased in malignant cells of IPMN, and FDG‐PET is useful for detecting malignancy of IPMN.
Title: S6 ribosomal protein phosphorylation is associated with malignancy of intraductal papillary mucinous neoplasm of the pancreas
Description:
AbstractBackgroundGlucose metabolism of intraductal papillary mucinous neoplasms (IPMNs) of the pancreas is unclear.
S6 ribosomal protein (S6) phosphorylation is involved not only in controlling cell growth but also in glucose metabolism in cancer.
The aim of this study was to investigate the role of S6 phosphorylation and the significance of glucose metabolic changes in IPMN.
MethodsRecords of 39 patients who underwent preoperative FDG‐PET and curative resection were enrolled in this study.
S6 phosphorylation and GLUT1 expression were evaluated immunohistochemically in these patients.
The effect of S6 phosphorylation on glucose uptake was examined in cancer cell lines.
To examine the change of glucose metabolism in IPMN clinically, the relation between clinical factors including FDG‐PET and malignancy of IPMN was investigated.
ResultsS6 phosphorylation and GLUT1 expression were significantly higher in carcinoma than in normal cells or adenoma.
Cell lines with high level of S6 phosphorylation showed high glucose uptake, and inhibition of S6 phosphorylation reduced glucose uptake.
In clinical examination, FDG‐PET was the independent factor related to the diagnosis of adenoma or carcinoma (odds ratio = 20.
0, 95% confidence interval = 1.
837‐539.
9, P = .
012).
FDG‐PET detected carcinoma with a sensitivity of 81.
8%, specificity of 96.
4%, and accuracy of 92.
3%.
ConclusionS6 phosphorylation was associated with glucose uptake and malignancy of IPMN.
Moreover, glucose uptake increased in malignant cells of IPMN, and FDG‐PET is useful for detecting malignancy of IPMN.
Related Results
Clinicopathological Features of Indeterminate Thyroid Nodules: A Single-center Cross-sectional Study
Clinicopathological Features of Indeterminate Thyroid Nodules: A Single-center Cross-sectional Study
Abstract
Introduction
Due to indeterminate cytology, Bethesda III is the most controversial category within the Bethesda System for Reporting Thyroid Cytopathology. This study exam...
Abstract 1502: DCLK1 labeling a unique pancreatic cellular lineage contributes to intraductal papillary mucinous neoplasm development
Abstract 1502: DCLK1 labeling a unique pancreatic cellular lineage contributes to intraductal papillary mucinous neoplasm development
Abstract
BACKGROUND & AIMS: Recently DCLK1 has been controversial as a biomarker of progenitor cells in both intestinal tract and pancreas. Pancreatic intraducta...
Cystic Lesion Mimicking Intraductal Papillary Mucinous Tumor Arising in Heterotopic Pancreas of the Stomach and Synchronous Intraductal Papillary Mucinous Adenocarcinoma of the Pancreas
Cystic Lesion Mimicking Intraductal Papillary Mucinous Tumor Arising in Heterotopic Pancreas of the Stomach and Synchronous Intraductal Papillary Mucinous Adenocarcinoma of the Pancreas
This article presents the study of a 66-year-old man with an asymptomatic pancreatic mass detected incidentally 4 months earlier. A magnetic resonance imaging scan revealed 2 disti...
CYTOLOGICAL CRITERIA OF PANCREATIC JUICE IN INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS
CYTOLOGICAL CRITERIA OF PANCREATIC JUICE IN INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS
Although it is not always easy to distinguish benign from malignant intraductal papillary mucinous neoplasms of the pancreas by the imaging techniques, the cytological examination ...
Endothelial Protein C Receptor
Endothelial Protein C Receptor
IntroductionThe protein C anticoagulant pathway plays a critical role in the negative regulation of the blood clotting response. The pathway is triggered by thrombin, which allows ...
Pancreatic cystic tumors: an update
Pancreatic cystic tumors: an update
Abstract
Pancreatic cystic tumors (PCTs) comprise a heterogeneous group of entities, accounting for 2% to 10% of pancreatic lesions. The most common types are intraduct...
Relationship between serum NDRG3 and papillary thyroid carcinoma
Relationship between serum NDRG3 and papillary thyroid carcinoma
BackgroundIn recent years, papillary thyroid carcinoma is considered to be one of the fastest increaseing cancer. NDRG family member 3 (NDRG3) has been proposed as a molecular mark...
Glucose metabolic upregulation via phosphorylation of S6 ribosomal protein affects tumor progression in distal cholangiocarcinoma
Glucose metabolic upregulation via phosphorylation of S6 ribosomal protein affects tumor progression in distal cholangiocarcinoma
Abstract
Background
The prognosis of distal cholangiocarcinoma (dCCA) remains poor; thus, the identification of new therapeutic targets is warranted...

